Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700886 | 0.90 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL15071341 | 0.86 | CYP1A2 (0.45) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL21853108 | 0.83 | CYP4F2 (0.46) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL26971249 | 0.82 | CYP1A2 (0.42) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL21853321 | 0.82 | CYP1A2 (0.42) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL3922208 | 0.82 | ALDH1A1 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL29547476 | 0.82 | DGKA (0.47) | ALDH1A1TSHR | |
| SCHEMBL196812 | 0.81 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL9438171 | 0.81 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL11061588 | 0.79 | TSHR (0.50) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-8741927-B2 | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD. (KR) | 2014-06-03 | — | — | US | disclosed |
| US-8741927-B2 | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD. (KR) | 2014-06-03 | — | — | US | disclosed |
| US-8741927-B2 | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD. (KR) | 2014-06-03 | — | — | US | disclosed |
| EP-2611776-A2 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG Life Sciences Ltd (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012030106-A2 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2012-03-08 | — | — | WO | disclosed |
| US-4456768-A | Chemical synthesis | THE UNIVERSITY OF CHICAGO (US) | 1984-06-26 | — | — | US | disclosed |
| US-4324730-A | Certain fluorine substituted PGI2 compounds | THE UNIVERSITY OF CHICAGO (US) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | CYP1A2 4533/4885GAA 4675/4885MGAM 3533/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | CYP1A2 3905/4885GAA 4698/4885MGAM 3353/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | CYP1A2 4533/4885GAA 4675/4885MGAM 3533/4885 |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | DPP4, DPP7, DPP8 | CYP1A2 315/4885GAA 69/4885MGAM 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.